Collegium Pharmaceutical, Inc. COLL Segment — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s segment — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s segment — interest income?
- Collegium Pharmaceutical, Inc. (COLL) reported segment — interest income of $3.71M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s segment — interest income changed year-over-year?
- Collegium Pharmaceutical, Inc.'s segment — interest income increased by 66.6% year-over-year, from $2.23M to $3.71M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s segment — interest income?
- Over 2 years (2022 to 2024), Collegium Pharmaceutical, Inc.'s segment — interest income has grown at a 265.4% compound annual growth rate (CAGR), from $1.05M to $13.98M.
- What does segment — interest income mean?
- This metric represents the total interest earned on cash balances, short-term investments, and other interest-bearing assets held by the business segment. It reflects the company's ability to generate passive returns on its excess liquidity and working capital. Monitoring this helps investors understand the non-operating income contribution from the segment's treasury management activities.